Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Poly(2-methacryloyloxyethyl phosphorylcholine) entrapped nimotuzumab nanocapsule, as well as preparation method and application thereof

A technology of methacryloyloxyethylphosphorylcholine and nimotuzumab, which is applied in the direction of microcapsules, nanocapsules, chemical instruments and methods, and can solve the problems of short blood drug half-life, immunogenicity, and large molecular weight. and other problems, to achieve the effect of avoiding toxic and side effects, inhibiting proliferation, and simple operation

Inactive Publication Date: 2016-06-15
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention aims to solve the problems of short blood half-life, immunogenicity, large molecular weight, and difficult penetration of the blood-brain barrier in current glioma antibody drugs, and proposes a poly 2-methacryloyloxyethyl phosphorylcholine Encapsulated nimotuzumab nano-microcapsules and its preparation method and use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Poly(2-methacryloyloxyethyl phosphorylcholine) entrapped nimotuzumab nanocapsule, as well as preparation method and application thereof
  • Poly(2-methacryloyloxyethyl phosphorylcholine) entrapped nimotuzumab nanocapsule, as well as preparation method and application thereof
  • Poly(2-methacryloyloxyethyl phosphorylcholine) entrapped nimotuzumab nanocapsule, as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Preparation and characterization of nimotuzumab nanocapsules encapsulated by poly-2-methacryloyloxyethyl phosphocholine

[0027] Take a solution containing 1 mg of Nimotuzumab (Baitai Biopharmaceutical Co., Ltd.), add the positive monomer N-(3-aminopropyl) methacrylate, Nimotuzumab and N-(3) The molar ratio of -aminopropyl) methacrylate is 1:300, and then add 2-methacryloxyethyl phosphocholine, nimotuzumab and 2-methacryloxyethyl phosphocholine The molar ratio of nimotuzumab to the cross-linking agent is 1:500; then the matrix metalloproteinase-2 degradable peptide cross-linking agent is added at the ratio of nimotuzumab to the cross-linking agent at a molar ratio of 1:500. Hydrogen bonding to enrich the reaction monomer and enzyme-degradable peptide cross-linking agent around the monoclonal antibody; then add ammonium persulfate and tetramethylethylenediamine, nimotuzumab and ammonium persulfate, tetramethylethyl The molar ratio of the diamine was 1:500:1000, a...

Embodiment 2

[0029] Example 2: Evaluation of the therapeutic effect of nimotuzumab nanocapsules coated with poly-2-methacryloxyethyl phosphocholine on U87 glioma in situ model in nude mice

[0030] The day before virus infection, U87 cells (ATCC, USA, HTB-14) were plated on a 24-well plate with a density of 1×10 5 -1×10 6 , At 5% CO 2 , Constant temperature culture at 37℃, the medium is DMEM medium (GBICO, USA, 11965-092), and the serum is imported calf serum (HyClone, SH30071.03). After 24h, add 10-500μl of virus solution encoding luciferase (Shanghai Jima Pharmaceutical Technology Co., Ltd.), and add 10-50μl of polybrene to increase the infection efficiency; after 12h, change to DMEM medium; after 48h Add the screening drug 10-100μl Puromycin, and after 2 weeks of pressure screening, positive clones are obtained, and the culture is expanded to prepare for transplantation into nude mice to establish an orthotopic model.

[0031] After the nude mouse is anesthetized and stabilized, make a surgi...

Embodiment 3

[0033] Example 3: Evaluation of the therapeutic effect of nimotuzumab nanocapsules coated with poly-2-methacryloxyethyl phosphocholine on the subcutaneous model of MGC803 gastric cancer in nude mice

[0034] Use a 100μl micro-injector to transfer MGC803 gastric cancer cells stably expressing luciferase to 5×10 per injection point. 5 The cells were inoculated subcutaneously in 4-week-old nude mice to establish the tumor source. When the subcutaneous tumor reached 3cm in length, the tumor mass was removed, evenly chopped, and implanted subcutaneously in nude mice of each experimental group (n=6), and feeding continued. When the long diameter reached about 5mm, each experimental group started treatment. The treatment method is tail vein injection, the treatment dose is 5 mg per kilogram of body weight, and the number of treatments is once. At the same time, the treatment effect was observed. The luciferase activity value of the tumor cells was collected by the in vivo imager every t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a poly(2-methacryloyloxyethyl phosphorylcholine) entrapped nimotuzumab nanocapsule, as well as a preparation method and application thereof. The nanocapsule is prepared by polymerizing poly(2-methacryloyloxyethyl phosphorylcholine) and nimotuzumab, has a smooth surface and a uniform grain size, and has a brain tumor targeting efficient delivery effect. The preparation method comprises the following steps: weighing 0.1-100mg of a nimotuzumab solution, and sequentially adding a monomer containing carbon-carbon double bond, a cross-linking agent and an initiator respectively according to the molar ratio of the nimotuzumab solution to the monomer containing carbon-carbon double bond, to the cross-linking agent and to the initiator being (1:100)-(1:100000), (1:100)-(1:10000), (1:100-1:10000); and preparing the nanocapsule by an in-situ polymerization method. The nanocapsule can be used for effectively inhibiting reproduction of glioma cells, and the curative effect of nimotuzumab for treating glioma cells can be improved.

Description

Technical field [0001] The invention belongs to the field of pharmaceutical preparations containing antigens or antibodies, in particular to a poly-2-methacryloxyethyl phosphorylcholine-encapsulated nimotuzumab nanocapsule, and a preparation method and application thereof. Background technique [0002] Glioblastoma is the most common primary intracranial malignant tumor and is highly aggressive. Current treatment options include surgical resection, adjuvant postoperative radiation and temozolomide chemotherapy, but the survival time is usually less than 15 months . In recent years, with the understanding of tumorigenesis and development mechanisms and the advancement of molecular biology technology, the clinic has begun to target cell receptors, key genes and regulatory molecules as molecular targeted therapy. The hot spots are mainly treatments targeting epidermal growth factor receptor (EGFR). EGFR is a transmembrane glycoprotein receptor. It consists of an extracellular liga...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/51A61K47/32A61K39/395A61P35/00
CPCA61K9/5138A61K39/3955A61K39/395A61K47/32A61K9/5192A61P35/00A61K47/58C07K16/2863
Inventor 康春生原续波卢云峰韩磊亓洪昭柳朝永王琦雪周俊虎
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com